Alliancebernstein L.P. Has $561,000 Stake in Intersect ENT, Inc. (NASDAQ:XENT)

Alliancebernstein L.P. continued to hold its stake in shares of Intersect ENT, Inc. (NASDAQ:XENT) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 32,720 shares of the medical equipment provider’s stock at the end of the first quarter. Alliancebernstein L.P. owned about 0.11% of Intersect ENT worth $561,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the company. Cornerstone Capital Management Holdings LLC. increased its position in Intersect ENT by 109.1% in the first quarter. Cornerstone Capital Management Holdings LLC. now owns 11,500 shares of the medical equipment provider’s stock valued at $196,000 after buying an additional 6,000 shares during the period. American International Group Inc. increased its position in shares of Intersect ENT by 7.1% in the first quarter. American International Group Inc. now owns 15,704 shares of the medical equipment provider’s stock worth $269,000 after buying an additional 1,037 shares during the last quarter. Russell Investments Group Ltd. purchased a new position in shares of Intersect ENT during the fourth quarter worth approximately $377,000. Boston Advisors LLC purchased a new position in shares of Intersect ENT during the first quarter worth approximately $482,000. Finally, Blair William & Co. IL increased its position in shares of Intersect ENT by 32.4% in the first quarter. Blair William & Co. IL now owns 39,900 shares of the medical equipment provider’s stock worth $543,000 after buying an additional 9,756 shares during the last quarter. Institutional investors and hedge funds own 72.78% of the company’s stock.

Intersect ENT, Inc. (NASDAQ:XENT) opened at 30.20 on Friday. The stock’s market cap is $881.51 million. The stock has a 50 day moving average of $28.87 and a 200-day moving average of $21.68. Intersect ENT, Inc. has a 52 week low of $7.65 and a 52 week high of $31.90.

Intersect ENT (NASDAQ:XENT) last posted its earnings results on Tuesday, August 1st. The medical equipment provider reported ($0.08) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.19) by $0.11. The company had revenue of $24 million during the quarter, compared to the consensus estimate of $22.62 million. Intersect ENT had a negative net margin of 22.94% and a negative return on equity of 17.60%. The company’s revenue for the quarter was up 24.4% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.21) earnings per share. Analysts forecast that Intersect ENT, Inc. will post ($0.61) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This story was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.com-unik.info/2017/08/19/intersect-ent-inc-nasdaqxent-position-maintained-by-alliancebernstein-l-p-updated.html.

A number of equities analysts recently commented on XENT shares. Zacks Investment Research downgraded shares of Intersect ENT from a “hold” rating to a “sell” rating in a research note on Wednesday, July 5th. William Blair restated an “outperform” rating on shares of Intersect ENT in a research note on Wednesday, May 10th. Northland Securities upped their target price on shares of Intersect ENT from $17.00 to $22.00 and gave the company an “outperform” rating in a report on Thursday, May 4th. Canaccord Genuity reaffirmed a “buy” rating on shares of Intersect ENT in a report on Wednesday, May 3rd. Finally, ValuEngine raised shares of Intersect ENT from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Five analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Intersect ENT presently has a consensus rating of “Buy” and a consensus price target of $23.13.

In other news, insider Lisa D. Earnhardt sold 20,000 shares of the business’s stock in a transaction on Thursday, June 15th. The shares were sold at an average price of $26.10, for a total value of $522,000.00. Following the completion of the sale, the insider now directly owns 583,493 shares in the company, valued at $15,229,167.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, COO Richard E. Kaufman sold 12,500 shares of the business’s stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $28.25, for a total transaction of $353,125.00. Following the completion of the sale, the chief operating officer now owns 169,821 shares of the company’s stock, valued at $4,797,443.25. The disclosure for this sale can be found here. Insiders sold 118,168 shares of company stock valued at $3,249,937 over the last 90 days. 13.70% of the stock is owned by corporate insiders.

Intersect ENT Company Profile

Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.

Institutional Ownership by Quarter for Intersect ENT (NASDAQ:XENT)

What are top analysts saying about Intersect ENT Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Intersect ENT Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit